Zavegepant (15) is constructed from three principal intermediates: the amino ester 15.14, the quinolone fragment 15.5, and the commercially available piperazine-piperidine building block 15.16, assembled in three steps . The amino ester fragment, (R)-2-amino-3-(7-methyl-1H-indazol-5-yl)propanoate (CAS 1414976-14-9), serves as the chiral core of Zavegepant, incorporating the 7-methylindazole moiety that is essential for CGRP receptor binding affinity . The quinolone intermediate, 3-(piperidin-4-yl)quinolin-2(1H)-one hydrochloride (CAS 855778-84-6), provides the rigid quinolone scaffold that contributes to the molecule's pharmacological profile . The piperazine-piperidine fragment, 1-(1-methylpiperidin-4-yl)piperazine trihydrochloride (CAS 349535-15-5), serves as the third coupling partner that completes the Zavegepant structure .
When your Zavegepant synthesis campaign requires reliable access to all three key intermediates, Cosperpharm delivers the complete intermediate series with the quality, documentation, and supply flexibility that pharmaceutical manufacturers demand.
Complete intermediate portfolio. Cosperpharm supplies the full Zavegepant intermediate series—the amino ester dihydrochloride (CAS 1414976-14-9), the quinolone hydrochloride (CAS 855778-84-6), and the piperazine trihydrochloride (CAS 349535-15-5). This comprehensive offering eliminates the need for multiple suppliers and streamlines your procurement process.
Quality you can trust. Every batch of each Zavegepant intermediate undergoes rigorous analytical release testing including HPLC purity verification, identity confirmation, and appearance inspection. Our quality system ensures that each intermediate meets the specifications required for efficient API synthesis—because your final product quality depends on the purity of every building block.
Documentation that supports regulatory submission. Each shipment includes a Certificate of Analysis (COA) with batch-specific purity data and chromatographic traceability. Custom quality agreements, stability summaries, and additional documentation are available upon request for customers requiring comprehensive regulatory support.
Flexible supply across all scales. Cosperpharm supplies Zavegepant intermediates from research quantities for process development and formulation studies to kilogram-scale batches for commercial manufacturing. R&D samples ship within 5–7 business days; bulk orders ship within 2–3 weeks.
Technical expertise for your synthetic strategy. Our chemistry team understands the nuances of Zavegepant synthesis and can provide technical support for coupling strategies, impurity profiling, and process optimization—because we have extensive experience with this API across multiple manufacturing campaigns.
Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and research institutes worldwide, with full customs documentation included. Volume discounts apply at larger scales, and we communicate lead times upfront.
Q1: What is Zavegepant?
A: Zavegepant (Zavzpret®) is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine in adults. It is administered as a nasal spray for rapid migraine relief.
Q2: What intermediates does Cosperpharm offer for Zavegepant synthesis?
A: Cosperpharm offers the full Zavegepant intermediate series: (R)-methyl 2-amino-3-(7-methyl-1H-indazol-5-yl)propanoate dihydrochloride (CAS 1414976-14-9), 3-(piperidin-4-yl)quinolin-2(1H)-one hydrochloride (CAS 855778-84-6), and 1-(1-methylpiperidin-4-yl)piperazine trihydrochloride (CAS 349535-15-5).
Cosperpharm has established a comprehensive quality assurance system for the Zavegepant intermediate series that meets the rigorous expectations of pharmaceutical API manufacturing:
Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing: HPLC purity verification, identity confirmation, and appearance inspection. The amino ester intermediate is characterized for chiral purity to ensure (R)-stereochemistry . The quinolone intermediate is verified for >98% purity . The piperazine-piperidine fragment is confirmed at >95% purity .
Full batch traceability. From raw material procurement through synthesis, purification, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with retention samples maintained in accordance with Cosperpharm quality procedures.
Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. Custom quality agreements, stability data, and additional documentation are available upon request for customers requiring comprehensive regulatory support.
Customer-initiated quality audits. Qualified customers are welcome to audit Cosperpharm's manufacturing, quality control, and documentation facilities. ISO compliance documentation is available upon request.
Looking for the full Zavegepant intermediate series for your API synthesis or pharmaceutical research? Cosperpharm offers all three key building blocks with the quality, documentation, and supply flexibility you need. Contact our team for pricing, availability, or technical questions—we're ready to support your Zavegepant project from research to commercial manufacturing.
![7-hydroxy-N,N,2-triMethyl-3-tosyl-3H-benzo[d]iMidazole-5-carboxaMide](https://www.cosperpharma.com/upload/8820/7-hydroxy-n-n-2-trimethyl-3-tosyl-3h-benzo-d-imidazole-5-carboxamide-681470.png "7-hydroxy-N,N,2-triMethyl-3-tosyl-3H-benzo[d]iMidazole-5-carboxaMide")
